VJHemOnc is committed to improving our service to you

EBMT 2020 | Post-transplant bendamustine for GvHD prophylaxis in refractory acute leukemia

VJHemOnc is committed to improving our service to you

Ivan Moiseev

Ivan Moiseev, MD, PhD, First Saint Petersburg State Medical University, Saint Petersburg, Russia, outlines the use of post-transplant bendamustine for GvHD prophylaxis as evaluated in a dose-escalation study in patients with refractory acute leukemias (NCT02799147). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter